#NASDAQ #United Kingdom #Edinburgh #TC BioPharm #OTC Markets

TC BioPharm's Transition to OTC Markets

In a significant development, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology firm specializing in allogeneic gamma-delta T cell therapies, has officially announced its shift from the Nasdaq Stock Market to the OTC Markets. This decision comes in wake of a ruling by the Nasdaq Hearings Panel, which determined that TC BioPharm would be delisted due to non-compliance with a critical listing rule.

Delisting Reasons and Company Response

On March 20, 2025, the Nasdaq Hearings Panel ruled that TC BioPharm failed to meet the requirement set out in Rule 5550(a)(2), which stipulates that listed securities must maintain a minimum bid price of $1.00 per share. In light of these developments, trading of TC BioPharm’s securities on Nasdaq will be suspended starting March 24, 2025. In response, the company's management is currently working on an appeal to reverse this decision, indicating their ongoing commitment to maintaining a presence in the market.

Transition to OTC Markets

As part of this transition, TC BioPharm has confirmed that its American Depositary Shares (ADS) will become eligible for trading on the OTC Markets as of the same date. This move aims to provide continued access for investors while the company navigates through its present challenges. It is noteworthy that despite this transition, TC BioPharm will still be required to fulfill its obligations regarding annual and interim reports to the SEC, adhering to federal securities laws.

Commitment to Innovation

Despite these hurdles, TC BioPharm remains steadfast in its mission to advance its innovative research and development initiatives. The company focuses on gamma-delta T cell therapies for treating various cancers, including acute myeloid leukemia, demonstrating human efficacy and holding potential as a pioneering treatment approach. TC BioPharm has established itself as a leader in this niche, being the first to conduct Phase II and pivotal clinical studies in oncology using these therapies.

Insight into Gamma-Delta T Cells

Gamma-delta T cells, which are naturally occurring immune cells, play a critical role in the immune response. They bridge the innate and adaptive immune systems, allowing for a unique ability to differentiate between healthy cells and those that are diseased. This characteristic underpins TC BioPharm's therapeutic strategies, showcasing the potential for these treatments to improve patient outcomes significantly.

Looking Ahead

Looking forward, TC BioPharm emphasizes its commitment to maintaining transparency and staying aligned with the community's interests. The company urges all stakeholders and potential investors to remain informed by carefully reviewing its public disclosures, including risks and uncertainties that could impact company performance and stock value.

Ultimately, while the transition from Nasdaq to OTC markets represents a significant shift, TC BioPharm aims to harness this change as a stepping stone towards achieving its long-term goals of innovation in cancer treatment. As it turns a new page, stakeholders are reminded to stay alert and engaged with the evolving story of TC BioPharm in the biopharmaceutical landscape.